Surmodics expects fiscal year 2019 revenue to range from $92M to $97M, consensus $90.37M. The company expects diluted EPS in the range of (32c) to (2c) per share, which reflects the company’s continued investment in research and development to further its whole-product solutions strategy. Non-GAAP diluted EPS is expected to be in the range of (7c) to 23c per share.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.